Incyte Cancels Ovarian Cancer Trial Planned For The Fourth Quarter Of 2026

The drugmaker attributed the decision to research priorities and expects its financial guidance and long-term outlook to be unaffected.

Share
Incyte Cancels Ovarian Cancer Trial Planned For The Fourth Quarter Of 2026

Incyte, which develops and sells medicines for blood disorders, cancer and inflammatory diseases, canceled a planned late-stage ovarian cancer trial Friday that was expected to begin in the fourth quarter of 2026. In its SEC filing, the company attributed the decision to research priorities and said it expects no effect on financial guidance or its previously announced long-term outlook.

An Ovarian Cancer Plan Dropped

The study, called MAESTRA-3, would have paired Incyte's experimental medicine INCB123667 with bevacizumab for initial maintenance treatment in ovarian cancer patients. INCB123667 targets CDK2, and the planned trial would have evaluated the combination in a late-stage study.

Incyte said it chose which research programs to prioritize. It said the cancellation was unrelated to safety findings or evidence about how well INCB123667 works from the drug's clinical testing.

Colorectal Cancer Research Continues

Incyte's cancer research includes a collaboration announced Tuesday with Natera, whose testing will help select participants for a mid-stage colorectal cancer trial. That study will test Incyte's experimental immunotherapy INCA33890 in patients who have finished surgery and follow-up chemotherapy.

Natera's Signatera test will identify patients whose molecular testing detects residual disease even though imaging shows none. The test will also help measure treatment outcomes.

Lois Erskine, Incyte's vice president and global program head for INCA33890, said these patients face a substantially higher risk of cancer returning after surgery and chemotherapy. The collaboration aims to address that treatment need.

Cancer Within A Broader Medicines Business

Incyte's business spans blood disorders, cancer, inflammation and autoimmune conditions. Its approved treatments include Jakafi for myelofibrosis, polycythemia vera and graft-versus-host disease, and Opzelura cream for atopic dermatitis and vitiligo.

The company sells medicines through pharmacies, distributors and wholesalers. It also receives royalties and milestone payments from medicines licensed to partners, including Novartis and Eli Lilly.

For holders, Incyte's stated expectation is that dropping the ovarian cancer study leaves both its financial guidance and long-term outlook unaffected.

Sources

More on Incyte

All Incyte (INCY) coverage →